keyword
https://read.qxmd.com/read/33717535/patients-with-asthma-or-chronic-obstructive-pulmonary-disease-copd-can-generate-sufficient-inspiratory-flows-via-easyhaler-%C3%A2-dry-powder-inhaler-a-pooled-analysis-of-two-randomized-controlled-trials
#21
JOURNAL ARTICLE
L Pekka Malmberg, Anna S Pelkonen, Ville Vartiainen, Mikko Vahteristo, Satu Lähelmä, Rain Jõgi
Background: To evaluate whether patients of varying ages and lung function with asthma or those with chronic obstructive pulmonary disease (COPD) can achieve sufficient inspiratory flows for effective use of the fixed-dose combination of salmeterol-fluticasone propionate and budesonide-formoterol dispensed with the Easyhaler® (EH) device-metered, multi-dose dry powder inhaler (DPI). Methods: A pooled analysis of two randomized, multicenter, crossover, open-label studies (NCT01424137; NCT009849061) was conducted to characterize inspiratory flow parameters across the EH, Seretide Diskus (DI) and Symbicort Turbuhaler (TH) inhalers in patients with asthma and/or COPD of varying severity...
February 2021: Journal of Thoracic Disease
https://read.qxmd.com/read/33600729/symbicort-given-as-needed-in-mild-asthma-sygma-study-a-retrospective-subanalysis-of-the-russian-population
#22
RANDOMIZED CONTROLLED TRIAL
Zaurbek Aisanov, Sergey Avdeev, Vladimir Arkhipov, Andrey Belevsky
INTRODUCTION: While mild asthma is generally better controlled than more severe disease, patients with mild asthma may experience severe exacerbations. Definite differences between countries in terms of asthma severity and control were described previously. Since SYGMA was a global study, this sub-analysis was conducted in geographic region to investigate potential regional specificities. METHODS: The SYGMA2 trial is double-blind multicenter study involving patients ≥12 years of age with mild asthma ( n  = 4176), eligible for regular treatment with inhaled corticosteroid (ICS)...
May 2022: Journal of Asthma
https://read.qxmd.com/read/33493074/real-life-association-between-inhaler-technique-patient-preference-and-asthma-control-in-patients-with-uncontrolled-asthma-switched-to-budesonide-formoterol-duoresp%C3%A2-spiromax%C3%A2-combination
#23
JOURNAL ARTICLE
Nicolas Roche, Bernard Aguilaniu, Simon Paternotte, Nathalie Dallery
Objective In asthma, treatment effectiveness is strongly influenced by the quality of inhaler use. New devices such as Spiromax® have been specifically developed to improve ease of use. It is crucial to determine whether switching to such a device improves inhaler technique and clinical outcomes, and to identify factors associated with handling errors. Methods This observational study assessed inhaler device handling errors in 1435 asthma patients recruited via 135 participating physicians in France, before and after switching therapy from the Symbicort Turbuhaler® or Seretide® Diskus® to DuoResp® Spiromax®...
January 25, 2021: Journal of Asthma
https://read.qxmd.com/read/33446624/expanded-table-correct-use-of-inhalers-for-asthma
#24
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
December 14, 2020: Medical Letter on Drugs and Therapeutics
https://read.qxmd.com/read/33446623/expanded-table-some-inhaled-drugs-for-treatment-of-asthma
#25
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
December 14, 2020: Medical Letter on Drugs and Therapeutics
https://read.qxmd.com/read/33446622/drugs-for-asthma
#26
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
December 14, 2020: Medical Letter on Drugs and Therapeutics
https://read.qxmd.com/read/33353682/symbicort-induces-orofacial-clefts-in-the-experimental-model-a-pilot-study
#27
JOURNAL ARTICLE
Miroslav Peterka, Lucie Hubickova Heringova, Andrej Sukop, Eva Manakova, Renata Peterkova
No abstract text is available yet for this article.
October 2020: Reproductive Toxicology
https://read.qxmd.com/read/33324041/budesonide-formoterol-anti-inflammatory-reliever-and-maintenance-or-fluticasone-propionate-salmeterol-plus-as-needed-short-acting-%C3%AE-2-agonist-real-world-effectiveness-in-patients-without-optimally-controlled-asthma-react-study
#28
JOURNAL ARTICLE
Shih-Lung Cheng, Ming-Lin Ho, Yun-Fa Lai, Hao-Chien Wang, Jeng-Yuan Hsu, Shih-Feng Liu, Ming-Shyang Huang, Cheng-Hung Lee, Ching-Hsiung Lin, Liang-Wen Hang, Yu-Chih Liu, Kuang-Yao Yang, Jia-Horng Wang
INTRODUCTION: In the prospective, observational, 16-week REACT study conducted between October 21, 2008 and May 12, 2011, we compared the real-world effectiveness of anti-inflammatory reliever and maintenance therapy with budesonide/formoterol (Symbicort® Turbuhaler) and maintenance therapy with fixed-dose fluticasone/salmeterol (Seretide® ) plus as-needed, short-acting β2 agonists (SABAs) in Taiwanese patients with inadequate asthma control. METHODS: Asthma control was assessed using the five-item Asthma Control Questionnaire (ACQ-5) and standardized pulmonary function testing...
2020: Drug Design, Development and Therapy
https://read.qxmd.com/read/33273812/a-comparison-of-the-real-life-clinical-effectiveness-of-the-leading-licensed-ics-laba-combination-inhalers-in-the-treatment-for-copd
#29
JOURNAL ARTICLE
Simon Wan Yau Ming, John Haughney, Dermot Ryan, Iain Small, Federico Lavorini, Alberto Papi, Dave Singh, David M G Halpin, John R Hurst, Shishir Patel, Matthias Ochel, Janwillem Kocks, Victoria Carter, Antony Hardjojo, David B Price
Introduction: The Fostair® 100/6 (BDP/FF) pressurized metered-dose inhaler, delivering an extrafine formulation, is licensed for asthma and COPD in the UK. However, its real-life effectiveness for COPD has not been evaluated. This study compared the clinical effectiveness of BDP/FF against other licensed ICS/LABA combination inhalers: the Seretide® Accuhaler® (FP/SAL) and the Symbicort® Turbohaler® (BUD/FF). Methods: A matched historical cohort study was conducted using records of patients with diagnostic codes for COPD from the Optimum Patient Care Research Database (OPCRD)...
2020: International Journal of Chronic Obstructive Pulmonary Disease
https://read.qxmd.com/read/33171338/ultra-high-performance-liquid-chromatography-method-development-for-separation-of-formoterol-budesonide-and-related-substances-using-an-analytical-quality-by-design-approach
#30
JOURNAL ARTICLE
Fadi L Alkhateeb, Ian Wilson, Margaret Maziarz, Paul Rainville
The application of the Quality by Design (QbD) principles in developing a new ultra high performance liquid chromatography method for the analysis of formoterol/budesonide and related substances using Fusion QbD® software is explored. The effect of various chromatographic parameters including, column stationary phase, pH, temperature, flow rate, and gradient time on separations were systematically investigated. Results show that optimal separations of these compounds in a standard solution can be achieved using a BEH C18 column (2...
October 29, 2020: Journal of Pharmaceutical and Biomedical Analysis
https://read.qxmd.com/read/33144930/assessment-of-inhalation-errors-training-time-and-patient-preference-for-duoresp%C3%A2-spiromax%C3%A2-and-symbicort%C3%A2-turbuhaler%C3%A2-in-patients-with-asthma-and-copd
#31
JOURNAL ARTICLE
Jordi Giner, Marta Villarnovo Cerrillo, Jaime Aboín Sierra, Laura Casas Herrero, Oliver Patino, Vicente Plaza
While poor inhaler technique in asthma and chronic obstructive pulmonary disease (COPD) can compromise the effectiveness of inhaled medications, identifying and quantifying these errors may suggest ways to improve inhalation technique and patient outcomes. The objective of this international, multicentre care improvement programme was to investigate errors in inhaler use (handling errors and inhalation errors) made by patients in handling two dry powder inhalers; DuoResp® Spiromax® and Symbicort® Turbuhaler®...
October 18, 2020: European Clinical Respiratory Journal
https://read.qxmd.com/read/33010810/effect-of-a-single-day-of-increased-as-needed-budesonide-formoterol-use-on-short-term-risk-of-severe-exacerbations-in-patients-with-mild-asthma-a-post-hoc-analysis-of-the-sygma-1-study
#32
RANDOMIZED CONTROLLED TRIAL
Paul M O'Byrne, J Mark FitzGerald, Eric D Bateman, Peter J Barnes, Jinping Zheng, Per Gustafson, Rosa Lamarca, Margareta Puu, Christina Keen, Vijay K T Alagappan, Helen K Reddel
BACKGROUND: In mild asthma, as-needed budesonide-formoterol reduces long-term exacerbation risk compared with as-needed short-acting β2 -agonist (SABA), with a similar or increased reduction versus maintenance with budesonide plus as-needed SABA, despite a lower budesonide dose. In this post-hoc analysis of the SYmbicort Given as needed in Mild Asthma (SYGMA) 1 study, we investigated the short-term risk of severe exacerbations after a single day with various levels of reliever use. METHODS: SYGMA 1 was a 52-week, double-blind, randomised, controlled, phase 3 trial, in which patients aged 12 years or older with mild asthma were randomly assigned (1:1:1) to placebo twice daily plus as-needed terbutaline 0·5 mg, placebo twice daily plus as-needed budesonide-formoterol 200-6 μg, or budesonide 200 μg twice daily plus as-needed terbutaline (ie, budesonide maintenance group)...
February 2021: Lancet Respiratory Medicine
https://read.qxmd.com/read/32836137/numerical-simulation-of-the-effect-of-inhalation-parameters-gender-age-and-disease-severity-on-the-lung-deposition-of-dry-powder-aerosol-drugs-emitted-by-turbuhaler%C3%A2-breezhaler%C3%A2-and-genuair%C3%A2-in-copd-patients
#33
JOURNAL ARTICLE
Alpár Horváth, Árpád Farkas, Annamária Szipőcs, Gábor Tomisa, Zsuzsanna Szalai, Gabriella Gálffy
The effect of breathing parameters on the airway deposition of the inhaled aerosols with known size was intensively studied in the literature. However, in the case of dry powder aerosol drugs both the quantity and quality of the particles emitted by the inhaler and inhaled by the patients is a complex function of the patient's breathing parameters, which in turn depend also on the disease severity and current status of the patient. The aim of this study was to evaluate the impact of breathing parameters, gender, age, symptoms and exacerbation history related disease severity (GOLD groups) of chronic obstructive pulmonary disease (COPD) patients on the lung dose of four different drugs emitted by three DPIs (dry powder inhalers)...
August 21, 2020: European Journal of Pharmaceutical Sciences
https://read.qxmd.com/read/32613551/first-approval-of-generic-dry-powder-inhaler-drug-products-in-japan
#34
JOURNAL ARTICLE
Ryosuke Kuribayashi, Aya Myoenzono
The Japanese Ministry of Health, Labour and Welfare (MHLW) published the basic principles of bioequivalence evaluations for generic dry powder inhaler (DPI) drug products in March 2016. The basic principles were formulated to promote the development of effective and safe generic DPI drugs. Based on this document, the Pharmaceuticals and Medical Devices Agency (PMDA) advises generic companies on effective development through consultation meetings. The PMDA generally requires data from in vitro tests, pharmacokinetic studies, and pharmacodynamic or clinical endpoint studies for generic drug development...
October 2020: Drug Delivery and Translational Research
https://read.qxmd.com/read/32095307/migrated-tubal-ligation-filshie-clip-as-an-uncommon-cause-of-chronic-abdominal-pain
#35
Sahil Sharma, Radek Martyniak, Vladislav Khokhotva
Tubal ligation (TL) is an effective and common method of fertility control. In the year 2009, over 24,000 were performed in Canada alone. Migration of Filshie clips used during TL is estimated to occur in 25% of all patients; 0.1-0.6% of these patients subsequently experience symptoms or extrusion of the clip from anatomical sites such as the anus, vagina, urethra, or abdominal wall. Migrated clips may present as chronic groin sinus, perianal sepsis, or chronic abdominal pain. These symptoms can occur as early as 6 weeks or as late as 21 years after application...
2020: Case Reports in Surgery
https://read.qxmd.com/read/32000396/a-randomized-controlled-trial-study-protocol-for-xiao-qing-long-decoction-in-the-treatment-of-refractory-asthma-study-protocol-clinical-trial-spirit-compliant
#36
JOURNAL ARTICLE
Hongjing Yang, Chuantao Zhang, Wenfan Gan, Jun Chen, Jianying Wu, Wei Xiao, Yang Yang, Keni Zhao, Zengtao Sun, Xiaohong Xie, Qingsong Huang
INTRODUCTION: People with refractory asthma (RA) often seek help from Chinese medicine due to dissatisfaction with conventional treatments. External cold and internal fluid syndrome is the most common type of asthma and the Chinese herbal medicine formula Xiao-Qing-Long (XQL) decoction is commonly prescribed for patients with asthma with this syndrome. However, there is no direct evidence to support the efficacy and safety of XQL decoction for RA treatment and its potential mechanism is still unclear...
January 2020: Medicine (Baltimore)
https://read.qxmd.com/read/31827932/dry-powder-and-budesonide-inhalation-suspension-deposition-rates-in-asthmatic-airway-obstruction-regions
#37
JOURNAL ARTICLE
Norihide Murayama, Kei Asai, Kikuno Murayama, Satoru Doi, Makoto Kameda
Steroid inhalation is the standard bronchial asthma therapy and it includes powdered metered doses, dry powder, and nebulizer suspension. However, particle sizes vary widely. The research goal was to demonstrate that different budesonide administration forms and devices have various deposition rates in the airway obstruction region. Here, we compared relative inhalation therapy efficacies and identified therapies that delivered the highest drug doses to the airway obstruction region. Weibel's anatomy data were used to identify the airway obstruction region in asthma...
2019: Journal of Drug Delivery
https://read.qxmd.com/read/31664463/-treatment-of-mild-asthma-steroids-in-eosinophil-negative-asthma-siena-and-novel-symbicort-turbuhaler-asthma-reliever-therapy-novel-start
#38
REVIEW
A Klemmer, C F Vogelmeier, S Nitschmann
No abstract text is available yet for this article.
December 2019: Der Internist
https://read.qxmd.com/read/31584145/as-needed-ics-laba-in-mild-asthma-what-does-the-evidence-say
#39
REVIEW
Christian Domingo, Jordi Rello, Ana Sogo
For the last three decades, the guidelines for asthma management have supported a stepwise therapeutic approach, based on the administration of controller medications (especially inhaled corticosteroids) complemented by on-demand use of rescue medication. Classically, the rescue medication recommended comprised short-acting β agonists (SABA). Some years ago, the use of Symbicort Maintenance and Reliever Therapy (SMART) demonstrated the benefits of a combination of budesonide-formoterol, an inhaled corticosteroid, and a long-acting β agonist (ICS-LABA) as rescue medication in moderate and severe asthma...
November 2019: Drugs
https://read.qxmd.com/read/31124982/asthma-associated-with-denatonium-benzoate-in-a-healthcare-worker-in-taiwan-a-case-report
#40
JOURNAL ARTICLE
Kou-Huang Chen, Kuo-Mou Chung, Ju-Hui Chung, Kow-Tong Chen
RATIONALE: Denatonium benzoate is a useful indicator to ensure that the respirator being used by an individual forms a tight enough seal to adequately protect against unwanted airborne exposure. Although the relative risk for adverse effects of fit testing using denatonium benzoate is low, the absolute number of workers with adverse reactions may nevertheless be sizeable. PATIENT CONCERNS: A 34-year-old female nurse rapidly developed shortness of breath, cough, and agitation after denatonium benzoate fit testing...
May 2019: Medicine (Baltimore)
keyword
keyword
32626
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.